RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis

Authors:

Abstract
No abstract available
Funding Information
  • Teva Neuroscience
  • Veterans Administration Merit (BX001458)
  • Foundation of the Consortium of Multiple Sclerosis Centers' MS Workforce of the Future
  • University of Maryland School of Medicine Office of Student Research
  • Leslie B. Barnett Memorial Student Fellowship
  • University of Maryland School of Medicine Office of Student Research

This publication has 21 references indexed in Scilit: